Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fred Saad

Showing results (91-100 of 1,123) with videos related to

Pageof 113
Sort By:
Therapeutic Advances in Medical Oncology|August 19, 2021
Relugolix: a novel androgen deprivation therapy for management of patients with advanced prostate cancerFred Saad, Neal D Shore
European Urology|December 12, 2003
Role of bisphosphonates in prostate cancerFred Saad, Claude C Schulman
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|February 7, 2012
Bisphosphonates: prevention of bone metastases in prostate cancerFred Saad, Jean-Baptiste Lattouf
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|August 6, 2025
Summary of changes in the 2025 Canadian Urological Association-Canadian Urologic Oncology Group guideline on metastatic castration-resistant prostate cancerFred Saad, Alan I So
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|December 31, 2010
Guidelines for the management of castrate-resistant prostate cancerFred Saad, Sebastien J Hotte
Current Opinion in Supportive and Palliative Care|July 18, 2018
Management of nonmetastatic castration-resistant prostate cancerSamer L Traboulsi, Fred Saad
The Canadian Journal of Urology|July 16, 2005
Low-risk prostate cancer patient: active treatmentJudd W Moul, Fred Saad
Journal of the American Board of Family Medicine : JABFM|January 6, 2012
Chemoprevention of prostate cancer: myths and realitiesPhilippe D Violette, Fred Saad
Therapeutic Advances in Urology|October 8, 2015
Abiraterone in the management of castration-resistant prostate cancer prior to chemotherapyBenjamin A Gartrell, Fred Saad
Seminars in Oncology|August 5, 2010
Zoledronic acid use in patients with bone metastases from renal cell carcinoma or bladder cancerFred Saad, James A Eastham
Pageof 113

Showing results (91-100 of 1,123) with videos related to

Sort By:
Pageof 113
Therapeutic Advances in Medical Oncology|August 19, 2021
Relugolix: a novel androgen deprivation therapy for management of patients with advanced prostate cancerFred Saad, Neal D Shore
European Urology|December 12, 2003
Role of bisphosphonates in prostate cancerFred Saad, Claude C Schulman
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|February 7, 2012
Bisphosphonates: prevention of bone metastases in prostate cancerFred Saad, Jean-Baptiste Lattouf
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|August 6, 2025
Summary of changes in the 2025 Canadian Urological Association-Canadian Urologic Oncology Group guideline on metastatic castration-resistant prostate cancerFred Saad, Alan I So
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|December 31, 2010
Guidelines for the management of castrate-resistant prostate cancerFred Saad, Sebastien J Hotte
Current Opinion in Supportive and Palliative Care|July 18, 2018
Management of nonmetastatic castration-resistant prostate cancerSamer L Traboulsi, Fred Saad
The Canadian Journal of Urology|July 16, 2005
Low-risk prostate cancer patient: active treatmentJudd W Moul, Fred Saad
Journal of the American Board of Family Medicine : JABFM|January 6, 2012
Chemoprevention of prostate cancer: myths and realitiesPhilippe D Violette, Fred Saad
Therapeutic Advances in Urology|October 8, 2015
Abiraterone in the management of castration-resistant prostate cancer prior to chemotherapyBenjamin A Gartrell, Fred Saad
Seminars in Oncology|August 5, 2010
Zoledronic acid use in patients with bone metastases from renal cell carcinoma or bladder cancerFred Saad, James A Eastham
Pageof 113